natgillin/translations-raw huggingface dataset:
A method of manufacturing an RNA interference oligonucleotide delivery composition comprising: forming an amphipathic membrane active polyamine, said membrane active polyamine is preferably obtainable by random polymerization of amine-containing monomers and lower hydrophobic group-containing monomers; or by random polymerization of amine-containing monomers, lower hydrophobic group-containing monomers and higher hydrophobic group monomers; 
tvorbu amfipatskog membranskog aktivnog poliamina, te se navedeni membranski aktivni poliamin poželjno može dobiti s nasumičnom polimerizacijom monomera koji sadrže amin i monomera koji sadrže nižu hidrofobnu skupinu; ili nasumičnom polimerizacijom monomera koji sadrže amin, monomera koji sadrže nižu hidrofobnu skupinu i monomera koji sadrže višu hidrofobnu skupinu;
A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. 
Prikladna zaštitna skupina za hidroksi skupine je, na primjer, acilna skupina, primjerice alkanoilna skupina poput acetila, aroilna skupina, primjerice benzoil, ili arilmetilna skupina poput benzila.
completely removing liquid, preferably at ambient temperature and at reduced pressure, from the second mixture; and recovering the rasagiline citrate or preparing the composition. Clause16. 
€) potpuno odstranjivanje tekućine iz druge smjese, prvenstveno pri temperaturi okoline i pri sniženom pritisku; i d) regeneriranje rasagilin citrata ili priprema sastava.
The pharmaceutical composition of claim 1 wherein the structural units represented by Formulae 1, 2, and 3 are represented by the following structures: 
Oralni oblik doziranja prema zahtjevu 1 naznačen time što Formula 1, Formula 2 i Formula 3 odgovaraju slijedećim strukturama:
A method for the generation of monoclonal antibodies (mAbs), wherein the antibodies constitute the basis for mixtures of antibodies produced by clonal cells the method comprising immunizing a transgenic murine mammal comprising integrated in its genome a nucleic acid molecule encoding a rearranged human immunoglobulin light chain variable region, wherein said light chain is capable of pairing with at least two different heavy chains encoded by the murine mammal, such that variety in specificity of antibodies is retained through rearrangements and hypermutations in the heavy chains, and wherein said light chain further comprises a murine light chain constant region, and isolating a nucleic acid molecule encoding at least part of such an antibody, inserting said nucleic acid molecule or a copy or a derivative thereof in an expression cassette and expressing said antibody in a host cell. 
Transgeni murinski sisavac, naznačen time, da posjeduje integriranu molekulu nukleinske kiseline u svojem genomu, koja kodira prerazmještaj varijabilnog područja humanog imunoglobulina slabog lanca, pri čemu se taj slabi lanac može spariti s najmanje dva različita jaka lanca koje kodiraju murinski sisavci, tako da se različitost u specifičnosti protutijela zadržava kroz prerazmještaje i hipermutacije u jakim lancima, gdje spomenuti slabi lanac nadalje sadrži stalno područje murinskog slabog lanca.
and pharmaceutically acceptable organic acids, for instance acetic acid, tartaric acid, maleic acid, hydroxymaleic acid, fumaric acid, citric acid, lactic acid, mucic acid, gluconic acid, benzoic acid, succinic acid, oxalic acid, phenylacetic acid, methanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, salicylic acid, sulfanilic acid, aspartic acid, glutamic acid and ascorbic acid. 
- i farmaceutski prikladnih organskih kiselina, na primjer octene, vinske, maleinske, hidroksimaleinske, mravlje, limunske, mliječne, mucinske, glukonske, benzojeve, sukcinatne, oksalne, feniloctene, methansulfonske, toluensulfonske, benzensulfonske, salicilatne, sulfanilne, aspartatne, glutaminske i askorbinske kiseline.
Space group: P21 Molecules of said compound/asymmetric unit: 4 wherein the unit cell parameters of Form N-1 are measured at a temperature of about -10 °C; and/or 
a = 0,941 nm b= 1,774 nm c= 3,194 nm a = 90.0° B = 98.4° Y = 90.0° Prostorna grupa: P21 Molekula spomenutog spoja/asimetrična jedinica: 4 pri čemu su parametri stanice Oblika N-1 mjereni na temperaturi od oko -10 °C; i/ili
A compound of formula (II): wherein: 
Spoj s formulom (II): [image] naznačen time da:
The process of clause 31, wherein the boronic ester compound of formula (I) present in the residue has a diastereomeric ratio of at least about 96:4 at the carbon atom bearing R1, R2, and R3, relative to a chiral center in the R4-R5 chiral moiety. 
Postupak prema patentnom zahtjevu 18 gdje spoj ester organoborne kiseline formule (7) koji je prisutan u ostatku ima diastereomerni odnos od najmanje 96:4 ili najmanje 97:3 na atomu ugljika koji nosi R', R* i R', u odnosu na hiralni centar u R'-R* hiralnoj grupi.
They can be used, alone or in combination, to treat neoplasms which in the past have been treated with methotrexate, including choriocarinoma, leukaemia, adenocarcinoma of the female breast, epidermid cancers of the head and neck, squamous or small-cell lung cancer, and various lymphosarcomas. 
Mogu se upotrijebiti, sami ili u kombinaciji, za tretiranje neoplazmi koju su se u prošlosti tretirale metotreksatom, uključivo koriokarcinom leukemija, adenokarcinom ženskih dojki, epidermid rakove glave i vrata, rak skvamoznih ili malih stanica pluća i različite limfosarkome.
Chromatography on a silica gel column (solvent: hexanes - ethyl acetate, 2:1) gave 9.66g of 42-O-(4-nitrophenyloxycarbonyl)rapamycin as a yellowish solid (freeze dried from benzene). 
Kromatografija na koloni silikagela (otapalo: heksani - etil-acetat, 2:1) dala je 9,66 g 42-O-(4-nitrofeniloksikarbonil)rapamicina kao žučkastu krutinu (osušeno smrzavanjem iz benzena).
The locking device (1) according to claim 1, wherein the movement system has at least one gear unit (5), and wherein the at least one gear unit (5) is driven by rotary movement of the at least one electric motor (4) and causes rotation of the at least one shaft. 
Zaporni uređaj (1) prema bilo kojem od prethodnih zahtjeva, naznačen time, da pokretački sustav ima najmanje jednu jedinicu zupčanika (5), posebno najmanje jedan uglasti zupčanik, pri čemu se navedena najmanje jedna jedinica zupčanika (5) pogoni pomoću rotacijskog pokretanja najmanje jednog električnog motora (4) i uzrokuje Totaciju osovine pokretačkog sustava.
For example, as shown in FIG. 26, a compound of Formula 9 (which may be formed as described above with respect to FIG. 19) may be protected as a 7,9-acetal linked analog of Formula 21 (where R1═R2═Ph; P1=TBDMS; R7═CH3; R8═R9═H in generalized formula 0 of Scheme 6). 
Na primjer, kao što je prikazano na slici 26, spoj formule 9 (koji može biti izveden kao što je gore opisano u odnosu na sliku 19) može biti zaštićen kao 7,9-acetalno povezani analog formule 21 (gdje R=R>=Ph; P,=TBDMS; Rg=CH;i Rg=R.o=H u općoj formuli O iz sheme 6).
Said improved fabric 10 comprises: a first inner layer 11, which is to be directed toward the body of the user and is substantially hydrophobic and breathable and is suitable to carry vapor-phase perspiration and liquid-phase perspiration away from the user of an item of clothing produced with said fabric 10, 
- < prvog unutarnjeg sloja (11, 111, 211, 411) koji je okrenut prema tijelu korisnika, koji je u biti hidrofoban i prozračan 1 koji je pogodan za izravno isparavanje tekućeg i parovitog znoja od korisnika odjevnog predmeta ili slično, proizvedenog uz pomoć navedene tkanine (10),
Examples of compounds for the present invention include natural ecteinascidins, such as ecteinascidin 743 and other 1,4 bridged fused ecteinascidin compounds disclosed for example in US 5,089,273, US 5,478,932, US 5,654,426, US 5,721,362, US 6,124,293, US 5,149,804, US 09/546,877, US 5,985,876 and WO 01/77115. 
Primjeri spojeva za predstavljeni izum obuhvaćaju prirodne ekteinascidine, kao što je ekteinascidin 743 i drugel,4 premošćene fuzionirane spojeve ekteinascidina opisane npr. u US 5,089,273, US 5,478,932, US 5,654,426, US 5,721,362, US 6,124,293, US 5,149,804, US 09/546,877, US 5,985,876 i WO 01/77115.
The method of claim 7, wherein the MEK pathway inhibitor is MEK inhibitor PD0325901 at a concentration of 0.8 µM to 1.2 µM, and the GSK3 inhibitor is CHIR99021 at a concentration of 2.5 µM to 3.5 µM. 
Postupak sukladno patentnom zahtjevu 7, naznačen time, da je inhibitor MEK puta MEK inhibitor PD0325901 u koncentraciji od 0,8 uM do 1,2 uM 1 GSK3 inhibitor je CHIR99021 u koncentraciji od 2,5 uM do 3,5 uM.
The freeze dried formulation according to any of the preceding claims, consisting of the following ingredients: rFSH, rLH, Tween 20, sucrose, methionine, a phosphate buffer. 
Smrzavanjem osušena formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da se sastoji od slijedećih sastojaka: rFSH, rLH, Tween 20, sukroze, metionina, fosfatnog pufera,
The method of claim 1, further comprising analyzing, using the processing apparatus, envelope characteristics of separated bands of the more than two frequency bands to identify the breath candidate, or comparing the values between identified minimum and said proportion of a maximum or proportional rise from a minimum, and optionally comprising identifying a degree of mathematic monotonicity of at least one separated band of the more than two frequency bands within a predetermined time and/or optionally comprising identifying the breath candidate if a sound signal has a comparable envelope shape in two or more frequency bands of the more than two frequency bands, and/or optionally further comprising using the monotonicity information to identify the intervals of time during which a search of minimums or maximums should take place. 
Postupak kao što je navedeno u bilo kojem od prethodnih zahtjeva, dalje sadržeći analizu karakteristika ovojnice odvojenih pojaseva zbog identifikacije kandidata daha, ili usporedbu vrijednosti između identificiranog minimuma 1 navedenog dijela maksimuma ili proporcionalnog rasta od minimuma, i opcionalno sadržeći identifikaciju stupnja matematičke monotonosti barem jednog odvojenog pojasa unutar predodređenog vremena, i/ili opcionalno sadržeći identifikaciju kandidata daha ako signal daha ima usporediv oblik ovojnice u dva ili više frekvencijska pojasa, i/ili opcionalno sadržeći korištenje podataka o monotonosti zbog identifikacije vremenskih intervala tijekom kojih bi se trebala odvijati potraga za minimumima ili maksimumima.
arginine; in the manufacture of a medicament for the treatment of cancer. 
(b) arginina; naznačena time, da je za proizvodnju lijeka za liječenje raka.
To improve the efficiency of dry powder compositions, the particles should be large while in the inhaler, but small when discharged into the respiratory tract. Thus, an excipient such as lactose, manitol or glucose is generally employed. 
Za poboljšanje učinkovitosti suhih praškastih pripravaka čestice trebaju biti velikih dimenzija u inhalatoru, ali malenih dimenzija kada se ispuste u respiratorni trakt, Stoga se općenito koriste ekscipijensi poput laktoze, manitola iti glukoze.
A combination of any one of claims 1 to 6 for use in the treatment or prevention of conditions which can be ameliorated by the inhibition of poly(ADP-ribose)polymerase (PARP). 
Spoj prema bilo kojem od zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, stereoizomer ili tautomer, naznačen time što služi za proizvodnju lijeka za liječenje ili prevenciju stanja koje može biti poboljšano inhibicijom poli(ADP-riboza)polimeraze (PARP).
Adsorb the solution from above step (b) onto the dry mix diluents of step 1 (a). 
Adsorbirajte otopinu i prethodnog koraka (b) na mješavinu suhih razrjeđivača iz koraka (a).
In some embodiments, the particle is biodegradable. 
Spoj sukladno zahtjevu 1, pri čemu je navedena čestica biorazgradiva.
The mobile station apparatus according to any of claims 1 to 8, wherein, in the second allocation, Localized Virtual Resource Blocks, LVRBs, are mapped to PRBs, and the LVRBs are allocated in units of the RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
A composition according to claim 6, wherein ivermectin is present in an amount in the range 0.1 to 10% (w/v). 
Smjesa prema zahtjevu 11, gdje je ivermektin prisutan u količini u rasponu 0.1 do 10% (t/v).
The use of claim 20 or 21, wherein the second agent is quinidine, and wherein the dosage amount of the compound of Formula I or pharmaceutically acceptable salt thereof is 10-60 mg, and the dosage amount of quinidine is 2.5-30 mg. 
Uporaba u skladu s patentnim zahtjevom 22 ili 23, pri čemu je drugi terapiski agens kinidin, 1 pri čemu je količina doziranja tvari formule I ili njene farmaceutski prihvatljive soli 10-60 mg, a količina doziranja kinidina je 2.5-30 mg.
A cured shaped extended release tablet comprising: at least one high molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight selected from 4,000,000 and 7,000,000; and 
Oblik za doziranje s produljenim otpuštanjem prema zahtjevu 11, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida koji ima, bazirano na reološkim mjerenjima, približnu molekulsku masu od barem 1,000,00.
overnight, and at room temperature. 
preko noći, na sobnoj temperaturi.
The components (B) are known. 
(B) spoj mandipropamid.
The results tabulated above clearly show that the enteric coat reduces by 4 orders of magnitude the level of formula (II) (and, by stoichiometry, thiol) formed by active under conditions which are typical of the human stomach. 
Rezultati prikazani u tablici iznad jasno pokazuju da enterička ovojnica smanjuje za 4 reda veličine razinu spoja formule (11) (1, stehiometrijski, tiola) kojeg formira aktivna tvar u uvjetima koji su tipični za ljudski želudac.
The method according to claim 11, wherein the subject has a central nervous system, and wherein the NE receptor is located in the central nervous system. 
D-metadon za uporabu prema zahtjevu 1, naznačen time što subjekt ima središnji živčani sustav i NE receptor se nalazi u središnjem živčanom sustavu.
is C6-10aryl optionally substituted with one to three R41 substituents independently selected from the group consisting of (C1-3)alkyl, C1-6)alkoxy, phenyl(C1-6)alkoxy; hydroxy; halogen; formylamino; aminocarbonyl; C1-6alkylaminocarbonyl; (C1-6alkyl)2aminocarbonyl; heterocyclylcarbonyl wherein heterocyclyl is a 5-7 membered nitrogen-containing ring and said heterocyclyl is attached to the carbonyl carbon via a nitrogen atom; carboxy; and cyano; provided that no more than one R41 substituent is formylamino, aminocarbonyl, C1-6alkylaminocarbonyl, (C1-6alkyl)2aminocarbonyl, heterocyclylcarbonyl, hydroxy, carboxy, or a phenyl-containing substituent. 
Crsalkilaminokarbonil; (C;.4alkil)aminokarbonil; heterociklilkarbonil pri čemu heterociklil je 5-7 člani prsten koji sadrži dušik i navedeni heterociklil je spojen na karbonil ugljik preko atoma dušika; karboksi; i cijano: uz uvjet da ne više od jedan R'' supstituent je formilamino, aminokarbonil, C,yalkilaminokarbonil, (Crgalkil),aminokarbonil, heterociklilkarbonil, hidroksi, karboksi ili supstituent koji sadrži fenil; je vodik ili metil; R* i R?
The method as claimed in claim 6, wherein the average rates of release of the hexoses are about from 2.8 to 5.6 g/L/h with a zero extracellular concentration of hexose, predominantly of glucose. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što prosječne brzine otpuštanja heksoza, pretežno glukoze, su otprilike od 2,8 do 5,6 g/l na sat, uz nultu izvanstaničnu koncentraciju heksoze, pretežno glukoze.
The multi-specific fusion protein of claim 1, wherein the CD86 binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:1-6. 
Multispecifični fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što domena za vezanje s CD86 sadrži aminokiselinski slijed koji se bira iz skupine koju čine SEQ ID NOS:1-6.
Whole blood was analyzed by Liquid Chromatography Mass Spectrometry for the presence of rapamycin. 
Puna krv analizirana je tekućinskom kromatografijom i masenom spektrometrijom da bi se utvrdila prisutnost rapamicina.
In this model, occlusive thrombus formation usually takes place within 15 to 20 minutes in non-treated animals. 
U ovom modelu, tvorba okluzivnog tromba se dešava obično unutar 15 do 20 minuta kod neliječenih životinja.
Optional additional ingredients include antimicrobials, plasticizers, and antifoaming agents. 
Izborni dodatni sastojci obuhvaćaju antimikrobna sredstva, plastifikatore i sredstva protiv stvaranja pjene.
The method according to claim 1, wherein in the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof R4 represents any of 
Spoj predstavljen formulom (1) ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time, da R4 predstavlja bilo koju od fenilne skupine,
The receiver is then deactivated by using its on-off switch. 
Prijemnik se tada isključuje korištenjem njegove on-off sklopke.
The herbicidal composition as claimed in claim 1, additionally comprising one or more further components selected from the group of agrochemical active compounds comprising insecticides, fungicides and safeners. 
Herbicidni pripravak prema zahtjevima 1 do 3, naznačen time da dodatno sadrži jednu ili više dodatnih komponenata iz skupine agrokemijski aktivnih spojeva koju čine insekticidi, fungicidi i zaštitna sredstva.
The topical veterinary composition of claim 1, wherein the 1-arylpyrazole active agent is fipronil. 
Topikalni veterinarski sastav prema zahtjevu 1, naznačen time, da djelatna tvar 1-arilpirazola je fipronil.
The chimeric human/mouse MHC I polypeptide of claim 13 or 14, wherein the human HLA class I polypeptide is a human HLA-A polypeptide (such as a HLA-A2 polypeptide, e.g. a HLA-A2.1 polypeptide) and the non-human animal MHC I polypeptide is a mouse H-2K polypeptide (such as a H-2Kb polypeptide). 
Kimerni ljudski/ne-ljudski, životinjski MHC-I-polipeptid prema zahtjevu 13 ili 14, naznačen time, da ljudski polipeptid HLA-razreda I je ljudski HLA-A-polipeptid (kao što je HLA-A2-polipeptid, primjerice HLA-A2.1-polipeptid) i ne-ljudski, životinjski MHC-I-polipetid je mišji H-2K-polipeptid (kao što je primjerice H-2Kb-polipeptid).
The method of claim 1, wherein the pharmaceutical composition comprises 0.1 mg to 200 mg of the compound, or a pharmaceutically acceptable salt thereof. 
19. Tvar ili njena farmaceutski prihvatljiva sol, ili sastav iz bilo kojeg od patentnih zahtjeva 1-18 za uporabu u 5
The reaction mixture was filtered through celite and washed with THF. 
Reakcijska smjesa je bila filtrirana kroz celit i isprana s THF.
A method for activating latent reservoirs of HIV comprising administering an effective amount of a phorbol ester of Formula II, a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, or polymorph thereof to said mammalian subject 
Pripravak za uporabu u prevenciji ili ublažavanju HIV-a u subjekta koji je sisavac, pripravak sadrži učinkovitu količinu forbolskog estera Formule II, ili njegove farmaceutski prikladne soli, izomera, enantiomera, solvata,
The post cure tire inflator of claim 1, wherein the first and second movable beams are movable via at least one pneumatic cylinder. 
Uređaj za pumpanje gume nakon vulkanizacije prema patentnom zahtjevu 1, naznačen time da su prvi i drugi pomični nosač (40, 42) pomični po barem jednom pneumatskom cilindru (46).
somewhat low, slight stupor, some exploratory movements with periods of immobility normal, alert, exploratory movements /slow freeze 
: nešto niža, lagani stupor, poneki eksploracijski pokret s razdobljima nepokretnosti: normalna, živahnost, eksploracjski pokreti/sporo,,zaleđivanje"
Pharmaceutical composition containing an RNA molecule according to claim 1, a pharmaceutically acceptable carrier and, optionally, further auxiliary substances, additives and/or adjuvants. 
Farmaceutski pripravak naznačen time da sadrži RNA molekulu prema zahtjevu 1, farmaceutski prihvatljiv nosač, te po izboru, dodatne pomoćne tvari, dodatke i/ili pomoćna sredstva.
The single immunoglobulin variable domain antibody according to any one of claims 1-11 for the use according to claim 13, wherein the disease is selected from the group consisting of systemic lupus erythematosis, Sjogren's syndrome, inflammatory bowel disease, Crohn's disease, and ulcerative colitis. 
Antitijelo sa jednim imunoglobulinskim varijabilnim domenom prema bilo kojem od patentnih zahtjeva 1-11 za primjenu prema patentnom zahtjevu 13, gdje je bolest odabrana iz grupe koja se sastoji od sistemskog eritematoznog lupusa, Sjogrenovog sindroma, upalne bolesti crijeva, Kronove bolesti, i ulceroznog kolitisa.
With this arrangement there is a minimum number of components in the outflow end 15, which can also be cleaned easily, optionally by sliding the sleeve 20 off the pipe section 43 and cleaning the outside of the plunger 21 from the outflow channel. 
Uz takvu izvedbu potreban je minimalan broj komponenti na izlaznom kraju 15, koji se isto tako može lako čistiti, moguće pomicanjem rukavca 20 s dijela cijevi 43 i čišćenja vanjskog dijela klipa 21 iz kanala za istjecanje.
The composition of any one of claims 1 to 14, further comprising a therapeutic agent selected from the group consisting of anesthetics, analgesics, anti-inflammatories, steroids, antibiotics, antiarthritics, anorectics, antihistamines and antineoplastics. 
Sastav iz bilo kojeg od patentnih zahtjeva 1 do 14, nadalje sadrži terapijski agens odabran iz grupe koja se sastoji od anestetika, analgetika, protuupalnih lijekova, steroida, antibiotika, antiartritika, anorektika, antihistaminika 1 antineoplastika.
Figure 4 is a schematic diagram illustrating the connection of the outputs of the receiver to various control devices provided with the boat, as well as connections with a battery and acoustic transducer, according to the present invention; 
Slika 4 je shematski dijagram koji prikazuje spajanje izlaza prijemnika na različite kontrolne uređaje koji postoje na plovilo, kao i spoj s baterijom i akustični davač, u skladu s opisanim izumom;
The pharmaceutical composition of claim 1, wherein the inhibition of antibody or antibody fragment aggregation is comparable to that of a lyophilized composition comprising sucrose, 0.01% polysorbate-20, pH 6.0, 50 mM Citrate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna da ona ima stabilnost koja odgovara onoj za liofiliziranu kompoziciju koja sadrži saharozu, 0,01 % polisorbata-20, pH 6,0, 50 mM citrata.
The process of claim 6, the increasing the concentration of hydrogen sulfide in the first liquid stream further comprising reducing a separation of hydrogen sulfide from the first liquid stream in a preceding distillation step. 
Postupak sukladno patentnom zahtjevu 6, povećanje koncentracije sumporovodika u prvom toku (1) tekućine nadalje sadrži redukciju odvajanja sumporovodika od prvog toka tekućine u prethodnom stupnju destilacije.
A method of inhibiting poly(ADP-ribose)polymerase (PARP) in a mammal in recognized need of such treatment comprising administering to the mammal a therapeutically acceptable amount of a compound of Formula (I) or a therapeutically acceptable salt thereof. A method of treating inflammation in a mammal in recognized need of such treatment comprising administering to the mammal a therapeutically acceptable amount of a compound of Formula (I) or a therapeutically acceptable salt thereof. 
Uporaba spoja Formule (I) u skladu s patentnim zahtjevom 1 ili njegova terapijski prihvatljiva sol, naznačena time, da se koristi za proizvodnju lijeka za inhibiciju poli(ADP-riboze)polimeraze (PARP) u sisavaca kod kojih je prepoznata potreba za takvim liječenjem putem primjene na sisavca terapijski prihvatljive količine rečenog spoja ili rečene terapijski prihvatljive količine rečenog spoja ili njegove terapijski prihvatljive soli.